Jack Kraeutler

Chairman & CEO

June 1, 2015

Jefferies 2015

Healthcare Conference

Forward Looking

Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by

meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A

of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as

“estimates”, “anticipates”, “projects”, “plans”, “seeks”, “may”, “will”, “expects”, “intends”, “believes”, “should” and similar expressions or the

negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current

expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-

looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These

statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation,

the following:

Meridian’s continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that

incorporate technological advances, meet customer requirements and respond to products developed by Meridian’s competition, and its ability to

effectively sell such products. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be

successful in the future in introducing such products on a timely basis. Meridian relies on proprietary, patented and licensed technologies, and the

Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing

consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary

pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change

expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug

Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. The international scope of

Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries,

can impact results and make them difficult to predict. One of Meridian’s growth strategies is the acquisition of companies and product lines. There can

be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be

successfully integrated into Meridian’s operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in

employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential

synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. The Company cannot predict the possible impact of U.S.

healthcare legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation

Act – and any modification or repeal of any of the provisions thereof, and any similar initiatives in other countries on its results of operations. In

addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks

and other matters that may affect the Company.

Meridian Bioscience, Inc.

Meridian

“VIVO”

Clinical Diagnostic

Tests

~$150 million

Life Science

Components

~$50million

~560 Employees 13 Worldwide Locations 70+ Global Markets >30 Regulatory Agencies

Clinical Diagnostic Tests

~$150 million

Hospital

Labs

Reference Labs

Outpatient

Clinics

Clinical Lab Diagnostics

Broad Testing

Platform Choices

Isothermal DNA Amplification

<60 minutes

1-10 tests/run

Rapidly expanding menu

Point-of-care

<15 minutes

Single use

Batch immunoassay

~2 hours

Up to 96/run

Life Science Components

~$50 Million

Large Dx

Manufacturers

Academic &

Private

Research

Biopharma

AgriBio

Rapidly

Growing

Asia

Markets

Meridian Bioscience

Global Presence

Sydney, Australia

Life Sciences (Bioline) sales,

warehouse, R&D and

manufacturing

Boca Raton, Florida

Life Sciences manufacturing

Memphis, Tennessee

Life Sciences manufacturing

• Life Sciences (Bioline) sales

and warehouse

Boston, Massachusetts

Cincinnati, Ohio

• Corporate headquarters

• U.S. Diagnostics

manufacturing, R&D, sales,

marketing and support

• Life Sciences / Diagnostics

Paris, France

• Life Sciences (Bioline) sales

warehouse, distribution, R&D,

manufacturing and admin.

London, United Kingdom

• European Diagnostics sales

and admin.

Boxtel, Netherlands

• Life Sciences (Bioline) sales,

warehouse and manufacturing

Luckenwalde, Germany

• Business Development office

Beijing, China

European Diagnostics sales

and admin.

Waterloo, Belgium

• European Diagnostics

distribution

Milan, Italy

• Distribution and sales

management

Singapore, Republic of

Singapore

Public Financial

Guidance

Net Sales

Growth(1)

$193 to $200M

+4%

$188.8

Flat

Diluted EPS

Growth(1)

$0.85 to $0.91

+6%

$0.83

-9%

(1)2014 growth calculated based on mid-point of range

FY 2015G FY 2014A

C. difficileLife Science

H. pylori

Foodborne

RespiratoryWomen’s

Health/STD

Other Dx

$32,000

$30,000+$2M

$25,000+$2M

$23,000+$6M

$7,000+$1M

$32,000

$48,000+$1M

2015 Estimate

Strategic Growth Contributors

Strategic Growth

Contributors ($000s)

$0

$10,000

$20,000

$30,000

$40,000

$50,000

$60,000

$70,000

$80,000

$90,000

Pre-analytics Life Science Molecular ImmunAssay NexGenPlatform

New

NewNew

New

New

Financially Efficient

0

5

10

15

20

25

2011 2012 2013 2014

ROA ROC

Gross Profit Margin 62%

Operating Income Margin 28%

Net Income Margin 18%

EBITDA Margin 32%

Industry-Leading Profitability Measures

Perc

ent

Six Months Ending March 31, 2015

Financially Efficient

0.0%

10.0%

20.0%

30.0%

40.0%

50.0%

60.0%

70.0%

80.0%

90.0%

100.0%Return on Invested Capital (ROIC)

WACC, 10.8%

The graph above shows the firm’s ROIC (excluding goodwill) compared with historical averages and WACC.

36.8%

47.2%

44.2%

94.2%

81.0%

67.9%

Dividend Yield as of 5/15/15 4.4%

Valuentum Securities/Seeking Alpha

April 29, 2015

RECENT DEVELOPMENTS

illumigene® Test Menu

HAI

C. difficile

C. difficile

Pediatric

STD

CT/NG

HSV-1 & 2

Blood

Related

Pathogens

eg. Babesia

eg. Malaria

Prenatal/

Women’s

Health

Group B

Strep

HSV-1 & 2

Respiratory

Group A

Strep

Mycoplasma

Pertussis

Foodborne

Campylobacter

Expand Number of

illumigene® Customers

125

~650

~950

~1,200~1,300

~1,400

0

200

400

600

800

1000

1200

1400

1600

Nov. 2010 Nov. 2011 Nov. 2012 Nov. 2013 Nov. 2014 Apr. 2015

•Approximately 75% U.S., 25% ROW

•Approximately 35% using multiple assays

illumigene® Pertussis

• Whooping cough is the only

reportable disease having

increasing trends

• Testing on adolescents and

young adults with a

prominent cough

• 20 million test potential

• Approximately 183

illumigene® Pertussis

customers to-date

Electrokinetic Sensor

Technology

• Accelerated surface

binding in minutes

• Minimum sample

preparation

• Capable of detecting

proteins and genetic

markers

Meridian Investment

Considerations

Favorable

Healthcare Trends

Clearly Defined

Growth Drivers

21% Return on Capital (LTM)

25 year Dividend Payout – Current yield 4+%

Innovative Products

Expanding product menu

New technologies for diagnostics and life science

Global expansion leverage

Aging population, emerging and re-emerging diseases

Commitment to improved healthcare outcomes

Founded 1977 – IPO 1986

Focused on decentralized testing; OEM supply

agreements; research markets

Multiple user-friendly technologies

FDA cleared diagnostics and innovative components

Durable Business

Model

Industry-Leading

Returns